WEST PHARMACEUTICAL SERVICES, INC. (WST)

Every figure this model derived for WST, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 225,300,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 444,300,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,807,500,000 AssetsCurrent 2026-06-30
current liabilities 640,500,000 LiabilitiesCurrent 2026-06-30
equity 2,990,200,000 StockholdersEquity 2026-06-30
interest expense 15,100,000 InterestExpenseDebt 2025-12-31
ocf 662,200,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 3,326,800,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 32,600,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up WST on one particular measure came for.

RatioValue
cash operating margin26.88
current ratio3.07
current ratio reported2.82
deferred revenue growth4.64
dilution pct-1.36
ebit cagr-2.15
ebit yoy16.99
fcf margin13.13
growth cv1.51
interest cover45.06
operating margin20.45
owner earnings margin12.15
revenue growth12.38
revenue growth per share13.93
roic19.52
rule of 4032.84
sbc pct revenue0.98

What to be careful about

What this model itself distrusts about WST's figures. Written by the derivation as it ran, not added afterwards.